The devastating consequences of alcohol-use disorder (AUD) on the individual and the society are well established. Current treatments of AUD encompass various strategies, all of which have only modest effectiveness. Hence, there is a critical need to develop more efficacious therapies. Recently, specific glutamatergic receptors have been identified as potential novel targets for intervention in AUD. Thus, the current study was designed to evaluate the effects of acute administration of sub-anesthetic doses of ketamine, an NMDA receptor antagonist, as well as NBQX, an AMPA/kainate receptor antagonist on alcohol intake and its possible behavioural consequences. Adult male Wistar rats were trained in drinking in dark paradigm (3 weeks), and following stable alcohol intake, ketamine, NBQX as well as their combination were injected prior to a 90 min drinking session. In addition to alcohol intake, sucrose preference (overnight), and locomotor activity and forced swim test (FST) were also evaluated before and following alcohol intake. Both doses of ketamine (5 and 10 mg/kg) and NBQX (5 and 10 mg/kg) significantly attenuated percent alcohol intake. The combination of the higher dose of ketamine and NBQX, however, did not significantly affect percent alcohol intake. Moreover, animals exposed to alcohol showed decreased sucrose intake (reflective of anhedonia), decreased locomotor activity and swimming in the FST (reflective of helplessness), that were not affected by ketamine and/or NBQX. These results suggest that selective antagonism of the NMDA or AMPA/kainate receptors may be of therapeutic potential in AUD.

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pharmacology Howard University College of Medicine Washington DC USA

Zobrazit více v PubMed

Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol. 2000;394:221–231. PubMed

Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40:749–760. PubMed

Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F. Acamprosate Produces Its Anti-Relapse Effects Via Calcium. Neuropsychopharmacology. 2014;39:783–791. PubMed PMC

Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Bachteler D, Gass P, Sprengel R, Spanagel R. Involvement of the AMPA Receptor GluR-C Subunit in Alcohol-Seeking Behavior and Relapse. J Neurosci. 2006;26:1231–1238. PubMed PMC

Vengeliene V, Bachteler D, Danysz W, Spanagel R. The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology. 2005;48:822–829. PubMed

Soto D, Altafaj X, Sindreu C, Bayés A. Glutamate receptor mutations in psychiatric and neurodevelopmental disorders. Commun Integr Biol. 2014;7:e27887. PubMed PMC

D’Souza MS. Glutamatergic transmission in drug reward: implications for drug addiction. Front Neurosci. 2015;9:404. doi: 10.3389/fnins.2015.00404. PubMed DOI PMC

Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl) 2013;229:539–554. PubMed PMC

Rao PSS, Bell RL, Engleman EA, Sari Y. Targeting glutamate uptake to treat alcohol use disorders. Front Neurosci. 2015;9:144. PubMed PMC

Roberts-Wolfe DJ, Kalivas PW. Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. CNS Neurol Disord Drug Targets. 2015;14:745–756. PubMed PMC

Getachew B, Hauser SR, Csoka AB, Taylor RE, Tizabi Y. Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants. Drug Alcohol Depend. 2017;175:133–139. PubMed PMC

Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacol Berl. 2013;230:291–8. PubMed PMC

Ketamine Advocacy Group. Provider Directory. [accessed March 16, 2017];Dir US Provid Ketamine Ther Depress Bipolar PTSD Mood Disord. 2015 http://www.ketamineadvocacynetwork.org/provider-directory/

Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349–352. PubMed

Ruda-Kucerova J, Babinska Z, Amchova P, Stark T, Drago F, Sulcova A, Micale V. Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats. World J Biol Psychiatry. 2017;18:129–142. PubMed

Goodwin FL, Amit Z. Do taste factors contribute to the mediation of ethanol intake? Ethanol and saccharin-quinine intake in three rat strains. Alcohol Clin Exp Res. 1998;22:837–844. PubMed

Amchova P, Kucerova J, Giugliano V, Babinska Z, Zanda M, Scherma M, Dusek L, Fadda P, Micale V, Sulcova A, Fratta W, Fattore L. Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Front Pharmacol. 2014;5:44. PubMed PMC

Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacol Berl. 1995;121:66–72. PubMed

Babinska Z, Ruda-Kucerova J. Differential characteristics of ketamine self-administration in the olfactory bulbectomy model of depression in male rats. Exp Clin Psychopharmacol. 2017;25:84–93. PubMed

Holgate JY, Shariff M, Mu EWH, Bartlett S. A Rat Drinking in the Dark Model for Studying Ethanol and Sucrose Consumption. Front Behav Neurosci. 2017;11:29. PubMed PMC

Rezvani AH, Levin ED, Cauley M, Getachew B, Tizabi Y. Ketamine differentially attenuates alcohol intake in male vs. female alcohol preferring (P) rats. J Drug Alc Res. 2017;2017:1–6. doi: 10.4303/jdar/236030. PubMed DOI PMC

Ruda-Kucerova J, Babinska Z, Stark T, Micale V. Suppression of methamphetamine self-administration by ketamine pre-treatment is absent in the methylazoxymethanol (MAM) rat model of schizophrenia. Neurotox Res. 2017;32:121–133. PubMed

Corlett PR, Honey GD, Fletcher PC. Prediction error, ketamine and psychosis: An updated model. J Psychopharmacol Oxf Engl. 2016;30:1145–1155. PubMed PMC

Long D, Long B, Koyfman A. The emergency medicine management of severe alcohol withdrawal. Am J Emerg Med. 2017 doi: 10.1016/j.ajem.2017.02.002. PubMed DOI

Holleran KM, Wilson HH, Fetterly TL, Bluett RJ, Centanni SW, Gilfarb RA, Rocco LER, Patel S, Winder DG. Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2016;41:2062–2071. PubMed PMC

Stephens DN, Brown G. Disruption of operant oral self-administration of ethanol, sucrose, and saccharin by the AMPA/kainate antagonist, NBQX, but not the AMPA antagonist, GYKI 52466. Alcohol Clin Exp Res. 1999;23:1914–1920. PubMed

Wang J, Ben Hamida S, Darcq E, Zhu W, Gibb SL, Lanfranco MF, Carnicella S, Ron D. Ethanol-mediated facilitation of AMPA receptor function in the dorsomedial striatum: implications for alcohol drinking behavior. J Neurosci Off J Soc Neurosci. 2012;32:15124–15132. PubMed PMC

Van Nest D, Hernandez NS, Kranzler HR, Pierce RC, Schmidt HD. Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats. Neurosci Lett. 2017;639:8–12. PubMed PMC

Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P. mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res. 2013;247:9–16. PubMed PMC

Bassareo V, Cucca F, Frau R, Di Chiara G. Changes in Dopamine Transmission in the Nucleus Accumbens Shell and Core during Ethanol and Sucrose Self-Administration. Front Behav Neurosci. 2017;11 doi: 10.3389/fnbeh.2017.00071. PubMed DOI PMC

Becker JB, Koob GF. Sex Differences in Animal Models: Focus on Addiction. Pharmacol Rev. 2016;68:242–263. PubMed PMC

Low Vs. High Alcohol: Central Benefits Vs. Detriments